Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award - PA: Regional Partnerships Program - Saskatchewan

University of Saskatchewan

$52,500.00

The Role of Insulin-like Growth Factor-1 (IGF-1) Signaling on Chronic Phase and Blast Crisis Phase of Chronic Myeloid Leukemia

FY 2011-12

Summary
Chronic Myelogenous Leukemia (CML) results when bone marrow cells acquire an abnormal enzyme called BCR-ABL. Newly developed drugs that inhibit the BCR-ABL enzyme show promise as agents to control CML. However, some patients do not to respond to these drugs or their disease eventually becomes resistant to their beneficial effects. Thus, it is important to more completely understand the mechanisms that regulate the growth properties of CML in order to develop new therapies to replace or complement current treatments. We have discovered that abnormal IGF-1 gene activity contributes to the aggressive growth properties and drug resistance of CML. The objective of this proposal is to determine the mechanisms by which IGF-1 confers these properties on CML cells. This information will be invaluable for improving CML diagnosis and identifying new therapies designed to eradicate the CML cells responsible for drug resistance.
Program
Doctoral Research Award - PA: Regional Partnerships Program - Saskatchewan
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
251422
Name
Abrishami Mahsa
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Saskatchewan Health Research Foundation
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The Role of Insulin-like Growth Factor-1 (IGF-1) Signaling on Chronic Phase and Blast Crisis Phase of Chronic Myeloid Leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$52,500
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA: Regional Partnerships Program - Saskatchewan
Keyworddelim
Chronic Myeloid Leukemia Stem Cells; Cytokines; Innate Imatinib Resistance Mechanisms; Insulin-Like Growth Factor And Drug Resistance In Leukemia
Abstract
Chronic Myelogenous Leukemia (CML) results when bone marrow cells acquire an abnormal enzyme called BCR-ABL. Newly developed drugs that inhibit the BCR-ABL enzyme show promise as agents to control CML. However, some patients do not to respond to these drugs or their disease eventually becomes resistant to their beneficial effects. Thus, it is important to more completely understand the mechanisms that regulate the growth properties of CML in order to develop new therapies to replace or complement current treatments. We have discovered that abnormal IGF-1 gene activity contributes to the aggressive growth properties and drug resistance of CML. The objective of this proposal is to determine the mechanisms by which IGF-1 confers these properties on CML cells. This information will be invaluable for improving CML diagnosis and identifying new therapies designed to eradicate the CML cells responsible for drug resistance.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Abrishami, Mahsa
Approvedterm
3 ans 0 mois
Cihrcontribution2
SPIR~ $52,500~ $0~
University of Saskatchewan - $52,500 Grant (2011-12) | Canada Spends